Screener
Climb Bio, Inc. CLYM Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Climb Bio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Climb Bio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210357
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity: | ||
| Common stock, $0.0001 par value; 250,000,000 shares authorized; 47,768,543 and 47,766,338 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 5 | 5 |
| Additional paid-in capital | 451,372 | 449,762 |
| Accumulated other comprehensive income | 157 | 435 |
| Accumulated deficit | (303,449) | (289,727) |
| Total stockholders’ equity | 148,085 | 160,475 |
| Total liabilities and stockholders’ equity | $152,372 | $167,744 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Climb Bio, Inc.'s total liabilities & equity?
- Climb Bio, Inc. (CLYM) reported total liabilities & equity of $152.37M in Q1 2026.
- How has Climb Bio, Inc.'s total liabilities & equity changed year-over-year?
- Climb Bio, Inc.'s total liabilities & equity decreased by 24.1% year-over-year, from $200.74M to $152.37M.
- What is the long-term trend for Climb Bio, Inc.'s total liabilities & equity?
- Over 5 years (2020 to 2025), Climb Bio, Inc.'s total liabilities & equity has grown at a 46.8% compound annual growth rate (CAGR), from $24.63M to $167.74M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Climb Bio, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude